HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM-Reference-Cited by-同舟云学术

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

Published:2015-02-13 Issue:7 Volume:29 Page:1496-1501
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Robin M,Porcher R,Adès L,Raffoux E,Michallet M,François S,Cahn J-Y,Delmer A,Wattel E^ORCID,Vigouroux S,Bay J-O,Cornillon J,Huynh A,Nguyen S,Rubio M-T,Vincent L,Maillard N,Charbonnier A,de Latour R P,Reman O,Dombret H,Fenaux P,Socié G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201537.pdf

Reference29 articles.

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. Scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

2. Greenberg, PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole f et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

3. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.

4. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662–2670.

5. Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012; 18: 1415–1421.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

2. Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes;Journal of Clinical Oncology;2024-08-20

3. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study;Leukemia Research;2024-07

4. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee;Blood;2024-05-30

5. Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen;Bone Marrow Transplantation;2024-05-23